ResearcherUniversity of California, Los AngelesActive in the last 2 years

Dustin L. Dillon

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-9272-4481; OpenAlex author ID A5040497555. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 5

Papers, trials and grants by year

2024: 1 paper

Papers 1

Neoadjuvant chemotherapy is associated with improved disease-free survival in pancreatic cancer patients undergoing pancreaticoduodenectomy with vascular resec… Co-author DOI 10.1002/jso.27674 ↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Timothy R. Donahue · 1 shared paper, 2024 · strength 0.23
- Paper Neoadjuvant chemotherapy is associated with improved disease-free survival in pancreatic cancer patients undergoing pan… DOI 10.1002/jso.27674 ↗
Michael A. Mederos · 1 shared paper, 2024 · strength 0.23
- Paper Neoadjuvant chemotherapy is associated with improved disease-free survival in pancreatic cancer patients undergoing pan… DOI 10.1002/jso.27674 ↗
Joon Y. Park · 1 shared paper, 2024 · strength 0.23
- Paper Neoadjuvant chemotherapy is associated with improved disease-free survival in pancreatic cancer patients undergoing pan… DOI 10.1002/jso.27674 ↗
Mark D. Girgis · 1 shared paper, 2024 · strength 0.23
- Paper Neoadjuvant chemotherapy is associated with improved disease-free survival in pancreatic cancer patients undergoing pan… DOI 10.1002/jso.27674 ↗
Jonathan C. King · 1 shared paper, 2024 · strength 0.23
- Paper Neoadjuvant chemotherapy is associated with improved disease-free survival in pancreatic cancer patients undergoing pan… DOI 10.1002/jso.27674 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.